FORTE BIOSCIENCES, INC. Research and Development Expense
FORTE BIOSCIENCES, INC. (FBRX) reported Research and Development Expense of $3.14 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-04-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-04-23
- FORTE BIOSCIENCES, INC. research and development expense for the quarter ending 2020-03-31 was $3.14M, a 74.74% decline year-over-year.
- FORTE BIOSCIENCES, INC. research and development expense for the quarter ending 2019-12-31 was $7.60M, a 51.37% decline year-over-year.
- FORTE BIOSCIENCES, INC. research and development expense for the quarter ending 2019-09-30 was $13.29M, a 8.42% increase year-over-year.
- FORTE BIOSCIENCES, INC. research and development expense for the quarter ending 2019-06-30 was $11.97M, a 6.18% decline year-over-year.
- FORTE BIOSCIENCES, INC. research and development expense for fiscal 2019 was $45.30M, a 11.32% decline from fiscal 2018.
- FORTE BIOSCIENCES, INC. research and development expense for fiscal 2018 was $51.08M, a 75.45% increase from fiscal 2017.
- FORTE BIOSCIENCES, INC. research and development expense for fiscal 2017 was $29.11M, a 6.96% increase from fiscal 2016.
- FORTE BIOSCIENCES, INC. research and development expense for fiscal 2016 was $27.22M, a 41.97% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $3.14M 10-Q · filed 2020-04-23 | $10.74M derived: sum of 2 quarters · filed 2020-04-23 | $24.03M derived: sum of 3 quarters · filed 2020-04-23 | $36.01M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $20.89M derived: sum of 2 quarters · filed 2020-02-27 | $32.87M derived: sum of 3 quarters · filed 2020-02-27 | $45.30M 10-K · filed 2020-02-27 |
| 2019-09-30 | $13.29M 10-Q · filed 2019-11-12 | $25.27M derived: sum of 2 quarters · filed 2019-11-12 | $37.70M 10-Q · filed 2019-11-12 | $53.32M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-06-30 | $11.97M 10-Q · filed 2019-08-08 | $24.41M 10-Q · filed 2019-08-08 | $40.03M derived: sum of 3 quarters · filed 2020-04-23 | $52.29M derived: sum of 4 quarters · filed 2020-04-23 |
| 2019-03-31 | $12.43M 10-Q · filed 2020-04-23 | $28.05M derived: sum of 2 quarters · filed 2020-04-23 | $40.31M derived: sum of 3 quarters · filed 2020-04-23 | $53.08M derived: sum of 4 quarters · filed 2020-04-23 |
| 2018-12-31 | $15.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $27.88M derived: sum of 2 quarters · filed 2020-02-27 | $40.64M derived: sum of 3 quarters · filed 2020-02-27 | $51.08M 10-K · filed 2020-02-27 |
| 2018-09-30 | $12.26M 10-Q · filed 2019-11-12 | $25.02M derived: sum of 2 quarters · filed 2019-11-12 | $35.46M 10-Q · filed 2019-11-12 | $43.76M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $12.76M 10-Q · filed 2019-08-08 | $23.20M 10-Q · filed 2019-08-08 | $31.49M derived: sum of 3 quarters · filed 2020-02-27 | $39.06M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $10.44M 10-Q · filed 2019-05-07 | $18.73M derived: sum of 2 quarters · filed 2020-02-27 | $26.29M derived: sum of 3 quarters · filed 2020-02-27 | $32.92M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $8.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $15.86M derived: sum of 2 quarters · filed 2020-02-27 | $22.49M derived: sum of 3 quarters · filed 2020-02-27 | $29.11M 10-K · filed 2020-02-27 |
| 2017-09-30 | $7.56M 10-Q · filed 2018-11-08 | $14.20M derived: sum of 2 quarters · filed 2018-11-08 | $20.82M 10-Q · filed 2018-11-08 | $27.45M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $6.63M 10-Q · filed 2018-08-09 | $13.26M 10-Q · filed 2018-08-09 | $19.89M derived: sum of 3 quarters · filed 2019-02-27 | $27.48M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $6.62M 10-Q · filed 2018-05-11 | $13.26M derived: sum of 2 quarters · filed 2019-02-27 | $20.84M derived: sum of 3 quarters · filed 2019-02-27 | $27.37M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $14.22M derived: sum of 2 quarters · filed 2019-02-27 | $20.75M derived: sum of 3 quarters · filed 2019-02-27 | $27.22M 10-K · filed 2019-02-27 |
| 2016-09-30 | $7.59M 10-Q · filed 2017-11-08 | $14.12M derived: sum of 2 quarters · filed 2017-11-08 | $20.59M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $6.53M 10-Q · filed 2017-08-09 | $13.00M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $6.47M 10-Q · filed 2017-05-23 | |||
| 2015-12-31 | $19.17M 10-K · filed 2018-03-09 |